Αρχική World News E-cigarettes: what we know and what we don’t

E-cigarettes: what we know and what we don’t

A man vaping

It’s been a decade since e-cigarettes first gained popularity in the UK. Since then, the types of devices available and the number of people using them has risen sharply.

And as the popularity levels of e-cigarettes grew, so did the debate around them.

The big selling point for e-cigarettes is they’re a way to help people stop smoking and reduce harm from the biggest cause of cancer in the world, tobacco.

But it’s a balancing act. E-cigarettes contain nicotine and so it’s important to make sure that people who have never smoked, particularly young people, don’t start to use them.

While it may be hard to remember a time before vaping, in the grand scheme of research, 10 years isn’t that long. And there’s still a lot more we need to understand about them.

Linda Bauld, Professor of Public Health at the University of Edinburgh and Cancer Research UK’s prevention adviser says, “These are still relatively new products. But a huge amount of research has been done. It’s a far more sophisticated discussion now than it was in the early years.”

Here are the big questions around e-cigarettes, what we know and what we still need to find out.

Is vaping safe?

Around 12,000 of us Google this each month in the UK. And you can understand why – there are a lot of mixed messages out there when it comes to e-cigarettes, with many headlines proclaiming that vaping is just as bad or worse than smoking.

In fact, research shows that vaping is far less harmful than smoking.

What are e-cigarettes/vapes?

E-cigarettes (also known as vapes) heat a liquid so that it becomes vapour and people can breathe it in. They usually contain nicotine which is the addictive chemical found in cigarettes.

Some studies have shown harmful effects of e-cigarette vapour. However, these are usually conducted on animals or cells in the lab, rather than in people. And the concentrations of e-cigarette vapour used are often much higher than people would be exposed to in real life.

Whilst these studies are useful to explore the potential effects of e-cigarettes, they shouldn’t be used to estimate real-world impact in humans.

The tone of the debate may also depend on where you live. In 2019, the US saw an outbreak of several thousand cases of respiratory illness and nearly 70 deaths linked to the use of vaping products. But again, headlines can be misleading, as these cases were due to contaminants in illegal products and not linked to regular vaping. There was no similar outbreak in the UK, and the chemicals of concern are banned.

The best evidence available in humans shows e-cigarettes are far less harmful than smoking. For example, one study found significantly lower levels of exposure to harmful chemicals in people who switch from smoking to vaping compared with those who continued to smoke. These levels were similar to people using nicotine replacement therapy (NRT). There’s also no good evidence that second-hand e-cigarette vapour is harmful to bystanders.

But e-cigarettes are a relatively new product. For this reason, there isn’t enough research into long-term use, or into their effects in people who have never smoked.

“In people who vape, the vast majority are smokers or ex-smokers. So unpicking the relationship between those two risks is really tough” says Bauld. “Definitive answers about safety may still take many years to identify”.

In short, there’s a lot more to learn.

But what researchers have had time to observe, over decades, is the huge amounts of research showing that tobacco is extremely harmful. Which is why experts can be confident that e-cigarettes are far less harmful than tobacco. This is broadly agreed by researchers and public health bodies.

Do e-cigarettes help people to stop smoking?

There’s growing evidence from around the world that e-cigarettes can help people stop smoking. In England, a study that looked at e-cigarette use and smoking cessation across the population estimated that e-cigarettes helped an additional 18,000 people in England in 2015 to quit for the long term.

Research shows the best way to stop smoking is through stop smoking services using a combination of counselling and prescription medication. We now have evidence that e-cigarettes combined with the behavioural support from stop smoking services are also effective in helping people to stop smoking.

Bauld says that smoking is still the largest preventable cause of cancer and is linked to 15 different types. “Supporting smokers to quit and young people to not start is a really important cancer prevention priority. So, if e-cigarettes can provide support for individuals as an aid to smoking cessation, then that’s of interest to cancer researchers.”

But there’s still a lot we need to find out. For example, there’s limited research into the role that different types of devices, nicotine concentrations and flavours play in helping people to stop smoking.

Although smoking rates in the UK continue to fall, levels in the most deprived populations are still much higher than in the least deprived, so experts are especially interested in whether e-cigarettes could help reduce this inequality. Recent research has suggested that people from lower socioeconomic groups might be more likely to use e-cigarettes, but it’s not yet clear whether this means e-cigarettes are improving smoking cessation rates in these communities.

Does vaping in young people lead to smoking?

Another question which often makes the headlines is around youth vaping and whether e-cigarettes are causing people to start smoking – the so-called ‘gateway effect’.

Overall, there’s no strong evidence for a gateway effect in the UK. Although experimentation with e-cigarettes among young people has increased in recent years, regular vaping in young people in the UK remains very low. In a representative survey of 11 to 18 year-olds in Great Britain in 2020, out of 1,926 never smokers, not a single person reported vaping daily.

Some research shows that young people who use e-cigarettes are more likely to smoke later on. But it’s a tricky relationship to untangle, as young people who smoke are more likely to vape. Experts have suggested that some young people are generally more likely to engage in ‘risky’ behaviours – like alcohol, drug use or smoking and vaping. Therefore, studies examining smoking and vaping in young people don’t necessarily show that vaping leads them to start smoking, but that they may be likely to do both anyway.

And the good news is that smoking rates and the perceptions around the acceptability of smoking have declined in young people, even since the introduction of e-cigarettes. So, it doesn’t seem like e-cigarettes have interfered with the promising drop in levels of smoking in young people.

Currently, the evidence doesn’t suggest that young people who have never smoked are vaping regularly, or that vaping is causing more young people in the UK to start smoking. But, vaping in young people is something we’re keeping an eye on.

Is it OK to smoke and vape at the same time?

There’s currently no evidence that using both cigarettes and e-cigarettes is worse than just smoking. But it’s clear that to get the health benefits, people need to switch completely from smoking to vaping.

And there are still unanswered questions here. It may be that some people go through a period where they both smoke and vape to help them quit, but right now we don’t know how long this transition period is, or how it varies from person to person.

Experts need to find out what causes people to switch from vaping and smoking to just vaping and how they can support people to do this.

Getting answers

Highlighting some of the main gaps in the current research, Bauld says that we don’t know enough about how people use e-cigarettes over time – including how use patterns change and if and when people stop using them. “We have some studies, but they’re really quite limited. We also don’t know enough about the impact of long-term use of these devices on health.”

At Cancer Research UK, we fund lots of research into the role of e-cigarettes in smoking cessation and their use in young people, which compliments research across the world to answer these big questions. And we work with policy makers to ensure that regulations match the rapidly evolving research in the area and engage with the public to ensure they receive accurate information.

In 2020, we took it one step further, uniting with the US National Cancer Institute to launch Cancer Grand Challenges – a global funding platform that supports world-class teams of researchers to take on some of the toughest challenges in cancer research. This includes a challenge focused on e-cigarettes, inviting the global research community to answer the big questions surrounding their use.

Large, long-term studies examining topics such as harms, youth use, use patterns over time, use of flavours and effectiveness in smoking cessation are needed.

And to get the answers we need about the effects of different regulations, these studies need to be conducted across the world. This will allow governments and health bodies to develop laws that protect young people from vaping, but also allow e-cigarettes to continue to be used to help people stop smoking.

There’s a lot we still need to know, but the evidence has come a long way so far. And all this evidence is why at Cancer Research UK, we recommend people who smoke consider using e-cigarettes as an option to help them quit, but why we would discourage people who have never smoked from starting to vape.

For up to date, accurate information on e-cigarettes, visit our webpage

Alice Davies is a health information officer at Cancer Research UK

More on this topic

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

10 Ways You Can Nurture A More Sustainable Garden

Sustainable gardening doesn’t have a firm, technical definition. It’s the concept of using sustainable gardening techniques that not only cause no harm to the...

Cancer Research UK spin-out gets US approval to trial unique T cell therapy

Cancer Research UK’s spin-out, GammaDelta Therapeutics (‘GammaDelta’), has been given approval from the US Food and Drug Administration (FDA) to trial its unique T-cell...

Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant Chemotherapy

The ECOG-ACRIN EA1131 study hypothesised that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype triple-negative breast cancer...

Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit [ESMO Virtual Plenary Press Release]

VP6-2021 - IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk,...

Breaking News: Supreme Court Upholds the Affordable Care Act

It’s a great day for cancer survivors. The Supreme Court of the United States (SCOTUS) upheld the Affordable Care Act (ACA), commonly known as...

How Does CAR T-Cell Therapy Work in Treating Cancer?

Craig A. Portell, MD, is an Associate Professor of Medicine at the University of Virginia and a member of the UVA Cancer Center in...